Survey of removing inhibitors in hemophilia A treatment
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be male
- You have hemophilia A (a problem with clotting factor VIII)
- Your clotting factor VIII level is in a severe, moderate, or mild range
- You either have an inhibitor level above 0.6 BU, or—if below that—your body is not using factor well (reduced recovery or shorter half-life)
- You can be included even if you tried and did not succeed with inhibitor removal before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This study looks at different ways to help blood clot in people with hemophilia who have developed inhibitors (proteins that stop standard clotting treatments from working). It may help doctors choose the safest, most effective clotting approach for these situations.
This study looks at how well a newer preventive treatment for hemophilia A works in everyday life. It collects real-world information from patients to help doctors tailor clotting therapy better.
This study tests a new approach to immune tolerance induction (ITI) in young people with severe hemophilia A who have a high-titer inhibitor. It uses a specific clotting factor combined with emicizumab to try to retrain the immune system so that standard treatments work again.
This trial studies a treatment approach for people with hemophilia A who develop antibodies (inhibitors) that block clotting factor FVIII. It may help those whose usual FVIII therapy is not working because of these inhibitors.
This study tests a new medicine called KN057 for people with hemophilia A or B, with or without inhibitors, to see if it helps prevent bleeding. It is for people who still have frequent bleeding episodes despite current treatments.
Hear when a new Haemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.